Cargando…

CRANAD-28: A Robust Fluorescent Compound for Visualization of Amyloid Beta Plaques

CRANAD-28, a difluoroboron curcumin analogue, has been demonstrated in earlier reports to successfully label amyloid beta (Aβ) plaques for imaging both ex vivo and in vivo. CRANAD-28’s imaging brightness, ability to penetrate the blood brain barrier, and low toxicity make the compound a potentially...

Descripción completa

Detalles Bibliográficos
Autores principales: Ran, Kathleen, Yang, Jing, Nair, Anil V., Zhu, Biyue, Ran, Chongzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070309/
https://www.ncbi.nlm.nih.gov/pubmed/32079064
http://dx.doi.org/10.3390/molecules25040863
_version_ 1783505945243942912
author Ran, Kathleen
Yang, Jing
Nair, Anil V.
Zhu, Biyue
Ran, Chongzhao
author_facet Ran, Kathleen
Yang, Jing
Nair, Anil V.
Zhu, Biyue
Ran, Chongzhao
author_sort Ran, Kathleen
collection PubMed
description CRANAD-28, a difluoroboron curcumin analogue, has been demonstrated in earlier reports to successfully label amyloid beta (Aβ) plaques for imaging both ex vivo and in vivo. CRANAD-28’s imaging brightness, ability to penetrate the blood brain barrier, and low toxicity make the compound a potentially potent imaging tool in Alzheimer’s research. In this study, the Aβ-labeling ability of CRANAD-28 was investigated in further detail using histological staining to assess different criteria, including stained Aβ plaque brightness, Aβ plaque size, and Aβ plaque number count. The results of this study demonstrated CRANAD-28 to be superior across all criteria assessed. Furthermore, CRANAD-28 and IBA-1 antibody were used to label Aβ-plaques and microglia respectively. Statistical analysis with Spearman regression revealed a statistically significant negative correlation between the size of labeled Aβ plaques and surrounding microglia density. This finding provides interesting insight into Aβ plaque and microglia dynamism in AD pathology and corroborates the findings of previous studies. In addition, we found that CRANAD-28 provided distinct spectral signatures for Aβs in the core and periphery of the plaques. Based on the study’s results, CRANAD-28 could be considered as an alternative standard for imaging Aβ-plaques in future research studies.
format Online
Article
Text
id pubmed-7070309
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-70703092020-03-19 CRANAD-28: A Robust Fluorescent Compound for Visualization of Amyloid Beta Plaques Ran, Kathleen Yang, Jing Nair, Anil V. Zhu, Biyue Ran, Chongzhao Molecules Article CRANAD-28, a difluoroboron curcumin analogue, has been demonstrated in earlier reports to successfully label amyloid beta (Aβ) plaques for imaging both ex vivo and in vivo. CRANAD-28’s imaging brightness, ability to penetrate the blood brain barrier, and low toxicity make the compound a potentially potent imaging tool in Alzheimer’s research. In this study, the Aβ-labeling ability of CRANAD-28 was investigated in further detail using histological staining to assess different criteria, including stained Aβ plaque brightness, Aβ plaque size, and Aβ plaque number count. The results of this study demonstrated CRANAD-28 to be superior across all criteria assessed. Furthermore, CRANAD-28 and IBA-1 antibody were used to label Aβ-plaques and microglia respectively. Statistical analysis with Spearman regression revealed a statistically significant negative correlation between the size of labeled Aβ plaques and surrounding microglia density. This finding provides interesting insight into Aβ plaque and microglia dynamism in AD pathology and corroborates the findings of previous studies. In addition, we found that CRANAD-28 provided distinct spectral signatures for Aβs in the core and periphery of the plaques. Based on the study’s results, CRANAD-28 could be considered as an alternative standard for imaging Aβ-plaques in future research studies. MDPI 2020-02-16 /pmc/articles/PMC7070309/ /pubmed/32079064 http://dx.doi.org/10.3390/molecules25040863 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ran, Kathleen
Yang, Jing
Nair, Anil V.
Zhu, Biyue
Ran, Chongzhao
CRANAD-28: A Robust Fluorescent Compound for Visualization of Amyloid Beta Plaques
title CRANAD-28: A Robust Fluorescent Compound for Visualization of Amyloid Beta Plaques
title_full CRANAD-28: A Robust Fluorescent Compound for Visualization of Amyloid Beta Plaques
title_fullStr CRANAD-28: A Robust Fluorescent Compound for Visualization of Amyloid Beta Plaques
title_full_unstemmed CRANAD-28: A Robust Fluorescent Compound for Visualization of Amyloid Beta Plaques
title_short CRANAD-28: A Robust Fluorescent Compound for Visualization of Amyloid Beta Plaques
title_sort cranad-28: a robust fluorescent compound for visualization of amyloid beta plaques
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070309/
https://www.ncbi.nlm.nih.gov/pubmed/32079064
http://dx.doi.org/10.3390/molecules25040863
work_keys_str_mv AT rankathleen cranad28arobustfluorescentcompoundforvisualizationofamyloidbetaplaques
AT yangjing cranad28arobustfluorescentcompoundforvisualizationofamyloidbetaplaques
AT nairanilv cranad28arobustfluorescentcompoundforvisualizationofamyloidbetaplaques
AT zhubiyue cranad28arobustfluorescentcompoundforvisualizationofamyloidbetaplaques
AT ranchongzhao cranad28arobustfluorescentcompoundforvisualizationofamyloidbetaplaques